Onishi T, Machida T, Masuda F, Suzuki M, Furuta N
Department of Urology, Jikei University School of Medicine.
Hinyokika Kiyo. 1990 Aug;36(8):879-85.
Patients with renal cell carcinoma treated at Jikei University and affiliated institutions were studied with regard to temporal differences. Our study population was divided into two groups: an earlier group comprising 169 patients treated between January 1957 and December 1979, and a later group comprising 165 cases treated between January 1980 and December 1984. The mean age in the earlier group was 56.2 years, while that in the later group was 60.4 years. Therefore, the patients in the earlier group were generally younger than those in the later group. Patients in the earlier group were more likely to present with urinary symptoms at the time of diagnosis. On the other hand, patients in the later group were more likely to present with extra-urinary symptoms or to be asymptomatic. The time period between the onset of symptoms and initial consultation with physician was longer (within one month) in the earlier group. Most patients in the later group underwent nephrectomy using the transperitoneal or thoracoabdominal approach. Few patients in the later group were treated with radiotherapy. As adjuvant chemotherapy, MFC (MMC, 5-FU and Ara-C) or MACV (methotrexate, actinomycin D, cyclophosphamide and vincristine) regimen were most commonly employed in the earlier group. FAV (5-FU, adriamycin and vinblastine) regimen or interferon therapy which was classified as biological response modifiers (BRM) were more commonly employed in the later group. More cases were diagnosed as stage II in the earlier group, and more cases were diagnosed as stage IV in the later group. No significant differences were observed between the earlier and later groups, with regard to 5- and 10-year survival rates.(ABSTRACT TRUNCATED AT 250 WORDS)
对在东京慈惠会医科大学及其附属医院接受治疗的肾细胞癌患者进行了时间差异方面的研究。我们的研究对象分为两组:早期组包括1957年1月至1979年12月期间接受治疗的169例患者,晚期组包括1980年1月至1984年12月期间接受治疗的165例患者。早期组的平均年龄为56.2岁,而晚期组为60.4岁。因此,早期组的患者总体上比晚期组的患者年轻。早期组的患者在诊断时更有可能出现泌尿系统症状。另一方面,晚期组的患者更有可能出现泌尿系统以外的症状或无症状。早期组症状出现与首次就医之间的时间间隔较短(在一个月内)。晚期组的大多数患者通过经腹或胸腹联合入路进行肾切除术。晚期组很少有患者接受放疗。作为辅助化疗,早期组最常用的是MFC(丝裂霉素、5-氟尿嘧啶和阿糖胞苷)或MACV(甲氨蝶呤、放线菌素D、环磷酰胺和长春新碱)方案。晚期组更常用FAV(5-氟尿嘧啶、阿霉素和长春碱)方案或被归类为生物反应调节剂(BRM)的干扰素治疗。早期组诊断为II期的病例更多,晚期组诊断为IV期的病例更多。在5年和10年生存率方面,早期组和晚期组之间未观察到显著差异。(摘要截断于250字)